Michael A. Thomas

rct 2022

Evaluation of ovulation and safety outcomes in a multi-center randomized trial of three 84 day ulipristal acetate regimens

Contraception ·doi:10.1016/j.contraception.2022.04.002

OBJECTIVES: To describe ovulation inhibition and safety of daily oral ulipristal acetate (UPA) over 84 days. STUDY DESIGN: This multi-center phase 1 and/or 2 trial randomized participants to use oral ulipristal 10 mg or 5 mg daily or a 3 c…

2017

Phthalates may alter macrophage signaling to promote a permissive environment for the initiation of endometriosis

·doi:10.1016/j.fertnstert.2017.07.963

review 2012

Ulipristal acetate as an emergency contraceptive agent

Expert opinion on pharmacotherapy ·doi:10.1517/14656566.2012.705832

INTRODUCTION: Emergency contraceptive agents play a crucial role in preventing unplanned pregnancy. These agents and devices have been studied since the 1960s and have had varied results in terms of side effects and efficacy. A new oral tab…

observational 2009

Follicle curetting at the time of oocyte retrieval increases the oocyte yield

Journal of assisted reproduction and genetics ·doi:10.1007/s10815-009-9323-9

PURPOSE: To determine whether follicle curetting at the time of oocyte retrieval increases oocyte yield. METHODS: Retrospective review of all patients who underwent oocyte retrieval from July 1, 2003 to June 30, 2005. MAIN OUTCOME MEASURE…

observational 2007

Intramuscular route of progesterone administration increases pregnancy rates during non-downregulated frozen embryo transfer cycles

Journal of assisted reproduction and genetics ·doi:10.1007/s10815-007-9168-z

OBJECTIVE: The optimal route of progesterone (P4) administration in embryo transfer (FET) cycles remains to be determined. The objective of this study is to compare the pregnancy outcomes between intramuscular (IM) and vaginal progesterone …